Related references
Note: Only part of the references are listed.International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI
Amy S. Ruppert et al.
BLOOD (2020)
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
Jie Zhu et al.
LEUKEMIA (2020)
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI
Jorne Biccler et al.
CANCER MEDICINE (2018)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
M. J. Maurer et al.
ANNALS OF ONCOLOGY (2018)
Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma
Rui Gao et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
Jihoon Kang et al.
BLOOD RESEARCH (2017)
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI
Carlos Montalban et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Sample size considerations for the external validation of a multivariable prognostic model: a resampling study
Gary S. Collins et al.
STATISTICS IN MEDICINE (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
Karel G. M. Moons et al.
ANNALS OF INTERNAL MEDICINE (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma
Wolfram Klapper et al.
BLOOD (2012)
Comparing the predictive powers of survival models using Harrell's C or Somers' D
Roger B. Newson
STATA JOURNAL (2010)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Share Paper
